Neoprobe, XTL deal

The companies completed their agreement under which NEOP received an exclusive right to license XTL's Trimera technology to develop activated cellular therapy and for producing human monoclonal antibodies for NEOP's RIGS targeting technology. (see BioCentury Jan. 22). ...